Skip to main
  1. Stocks
  2. Humacyte
  3. Forecast
HUMA

Humacyte (HUMA) Stock Forecast & Price Target

Humacyte (HUMA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 57%
Buy 14%
Hold 29%
Sell 0%
Strong Sell 0%

Bulls say

Humacyte is supported by improving commercial traction, with 3Q26 revenue of about $1.0M rising 36.5% year over year, roughly 60 Symvess units sold, and hospital ordering sites increasing 44% quarter over quarter to 49, while management expects revenue to double in 4Q26 as at least 20 new hospital sites come on board. Its fundamental thesis is strengthened by the V012 interim data, where the ATEV achieved 220 catheter-free days versus 129 for standard care, met the primary efficacy endpoint with p=0.00070, and showed a favorable safety profile with lower infection rates and zero access-associated infections in the ATEV cohort. The company also has a meaningful near-term catalyst in the November supplemental BLA filing for dialysis access, which could unlock a much larger market than vascular trauma while operating spend reductions and the $50M equity offering help reduce financial overhang.

Bears say

Humacyte is facing a fundamental mismatch between commercial ambition and execution, as 2Q revenue of $0.4 million fell well below the $1.1 million consensus and the company’s $1.2 million estimate, while it still reported operating losses since inception and may not achieve profitability for several years. The outlook is further pressured by clinical, regulatory, and manufacturing uncertainty, including the risk of longer trial enrollment, poor clinical outcomes, and whether a comparability demonstration between the former and new manufacturing process will be accepted by the FDA. Although restructuring is forecasted to reduce spending by $14.3 million for the remainder of 2026, commercialization remains difficult to predict, and the company may need additional capital and dilution while market adoption for ATEVs remains uncertain.

Humacyte (HUMA) has been analyzed by 7 analysts, with a consensus rating of Buy. 57% of analysts recommend a Strong Buy, 14% recommend Buy, 29% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Humacyte and is not a guaranteed prediction by Public.com or investment advice.

Humacyte (HUMA) Analyst Forecast & Price Prediction

Get the latest Humacyte (HUMA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Humacyte (HUMA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Humacyte (HUMA) Forecast

Analysts have given Humacyte (HUMA) a Buy based on their latest research and market trends.

According to 7 analysts, Humacyte (HUMA) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.98, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.98, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Humacyte (HUMA)


Humacyte (HUMA) Analyst Forecast & Price Prediction

Get the latest Humacyte (HUMA) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Humacyte (HUMA)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover HUMA stock data and trends